Investor Relations

News Releases

<< Back
Jan 24, 2018
Intersect ENT to Present at the 7th Annual LEERINK Partners Global Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Jan. 24, 2018-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will be presenting at the 7th Annual LEERINK Partners Global Healthcare Conference on Wednesday, February 14, 2018 at 2:30 p.m. ET at the Lotte New York Palace Hotel.

A live webcast of the presentation will be available online from the Investor Relations page of the company's website at www.IntersectENT.com. The webcast replay will be available for approximately one month.

About Intersect ENT®

Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

For additional information on the company or the products including risks and benefits please visit www.IntersectENT.com.

XENT-F

Source: Intersect ENT, Inc.

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105
ir@intersectENT.com